Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro TLR4 Stimulating Bioactivities of Amylase/Trypsin-Inhibitors from Wheat (<i>Triticum aestivum</i> L.) Bred from 1891 to 2010.

Foods (Basel, Switzerland)·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.

United European gastroenterology journal·2026
Same author

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

BMC medicine·2026
Same author

Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease.

Scientific reports·2026
Same author

ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis.

Hepatology (Baltimore, Md.)·2026

Related Experiment Video

Updated: Mar 9, 2026

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.8K

Optimized Mouse Models for Liver Fibrosis.

Yong Ook Kim1, Yury Popov2, Detlef Schuppan3,4

  • 1Institute of Translational Immunology and Research Center for Immune Therapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

Methods in Molecular Biology (Clifton, N.J.)
|January 8, 2017
PubMed
Summary

This study details optimized mouse models for liver fibrosis research. These models aid in understanding fibrosis mechanisms and developing antifibrotic therapies for liver diseases like cirrhosis.

Keywords:
Biliary fibrosisCarbon tetrachloride (CCL4)CirrhosisCollagenExtracellular matrix (ECM)FibrosisHydroxyproline (HYP)Liver fibrosisMdr2-knockoutMetavir stagingPanlobular fibrosisPicrosirius RedThioacetamide (TAA)

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.4K

Related Experiment Videos

Last Updated: Mar 9, 2026

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.8K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.1K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.4K

Area of Science:

  • Hepatology
  • Pathology
  • Translational Medicine

Background:

  • Fibrosis involves excessive extracellular matrix accumulation, primarily collagen, due to chronic injury.
  • Liver fibrosis can advance to cirrhosis, causing hepatic vascular distortion, impaired blood flow, and liver failure.
  • Cirrhosis significantly increases morbidity, mortality, and the risk of primary liver cancer.

Purpose of the Study:

  • To describe optimized mouse models for studying liver fibrosis.
  • To present state-of-the-art methods for assessing fibrosis in these models.
  • To facilitate the development of antifibrotic therapies.

Main Methods:

  • Utilized optimized mouse models to induce and study liver fibrosis.
  • Employed advanced techniques for fibrosis assessment and readout.
  • Focused on cellular and molecular mechanisms underlying fibrosis progression.

Main Results:

  • Successfully established and characterized specific mouse models of liver fibrosis.
  • Demonstrated the utility of these models in recapitulating key aspects of human liver fibrosis and cirrhosis.
  • Validated state-of-the-art fibrosis readouts for accurate assessment.

Conclusions:

  • Optimized mouse models are crucial for investigating liver fibrosis pathogenesis.
  • These models support the preclinical development of targeted antifibrotic strategies.
  • Advanced fibrosis readouts enhance the reliability of preclinical research findings.